Last reviewed · How we verify

Belantamab mafodotin frozen liquid

GlaxoSmithKline · Phase 2 active Small molecule

Belantamab mafodotin frozen liquid is a Monoclonal antibody-drug conjugate Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Multiple myeloma.

Belantamab mafodotin is a monoclonal antibody-drug conjugate that targets BCMA.

Belantamab mafodotin is a monoclonal antibody-drug conjugate that targets BCMA. Used for Multiple myeloma.

At a glance

Generic nameBelantamab mafodotin frozen liquid
SponsorGlaxoSmithKline
Drug classMonoclonal antibody-drug conjugate
TargetBCMA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

It binds to BCMA on the surface of multiple myeloma cells, delivering a cytotoxic agent that kills the cells. This approach is designed to minimize damage to healthy cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Belantamab mafodotin frozen liquid

What is Belantamab mafodotin frozen liquid?

Belantamab mafodotin frozen liquid is a Monoclonal antibody-drug conjugate drug developed by GlaxoSmithKline, indicated for Multiple myeloma.

How does Belantamab mafodotin frozen liquid work?

Belantamab mafodotin is a monoclonal antibody-drug conjugate that targets BCMA.

What is Belantamab mafodotin frozen liquid used for?

Belantamab mafodotin frozen liquid is indicated for Multiple myeloma.

Who makes Belantamab mafodotin frozen liquid?

Belantamab mafodotin frozen liquid is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Belantamab mafodotin frozen liquid in?

Belantamab mafodotin frozen liquid belongs to the Monoclonal antibody-drug conjugate class. See all Monoclonal antibody-drug conjugate drugs at /class/monoclonal-antibody-drug-conjugate.

What development phase is Belantamab mafodotin frozen liquid in?

Belantamab mafodotin frozen liquid is in Phase 2.

What are the side effects of Belantamab mafodotin frozen liquid?

Common side effects of Belantamab mafodotin frozen liquid include Neutropenia, Thrombocytopenia, Anemia, Fatigue, Nausea, Diarrhea.

What does Belantamab mafodotin frozen liquid target?

Belantamab mafodotin frozen liquid targets BCMA and is a Monoclonal antibody-drug conjugate.

Related